Literature DB >> 28881920

Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

R Glynne-Jones1, L Wyrwicz2, E Tiret3,4, G Brown5, C Rödel6, A Cervantes7, D Arnold8.   

Abstract

Entities:  

Mesh：

Year:  2017        PMID： 28881920     DOI： 10.1093/annonc/mdx224

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  313 in total

1.  Cell-free DNA and preoperative chemoradiotherapy for rectal cancer: a systematic review.

Authors:  Anders Kindberg Boysen; Jakob Vasehus Schou; Karen-Lise Garm Spindler
Journal:  Clin Transl Oncol       Date:  2018-12-01       Impact factor: 3.405

2.  Transcriptomic Differences between Primary Colorectal Adenocarcinomas and Distant Metastases Reveal Metastatic Colorectal Cancer Subtypes.

Authors:  Yasmin Kamal; Stephanie L Schmit; Hannah J Hoehn; Christopher I Amos; H Robert Frost
Journal:  Cancer Res       Date:  2019-06-25       Impact factor: 12.701

3.  Circulating Tumour DNA as a Potential Cost-Effective Biomarker to Reduce Adjuvant Chemotherapy Overtreatment in Stage II Colorectal Cancer.

Authors:  Yat Hang To; Koen Degeling; Suzanne Kosmider; Rachel Wong; Margaret Lee; Catherine Dunn; Grace Gard; Azim Jalali; Vanessa Wong; Maarten IJzerman; Peter Gibbs; Jeanne Tie
Journal:  Pharmacoeconomics       Date:  2021-06-05       Impact factor: 4.981

4.  Neoadjuvant (Chemo)radiotherapy With Total Mesorectal Excision Only Is Not Sufficient to Prevent Lateral Local Recurrence in Enlarged Nodes: Results of the Multicenter Lateral Node Study of Patients With Low cT3/4 Rectal Cancer.

Authors:  Atsushi Ogura; Tsuyoshi Konishi; Chris Cunningham; Julio Garcia-Aguilar; Henrik Iversen; Shigeo Toda; In Kyu Lee; Hong Xiang Lee; Keisuke Uehara; Peter Lee; Hein Putter; Cornelis J H van de Velde; Geerard L Beets; Harm J T Rutten; Miranda Kusters
Journal:  J Clin Oncol       Date:  2018-11-07       Impact factor: 44.544

5.  Therapeutic effects and limitations of chemoradiotherapy in advanced lower rectal cancer focusing on T4b.

Authors:  Kosuke Ozaki; Kazushige Kawai; Hiroaki Nozawa; Kazuhito Sasaki; Koji Murono; Shigenobu Emoto; Yuuki Iida; Hiroaki Ishii; Yuichiro Yokoyama; Hiroyuki Anzai; Hirofumi Sonoda; Kenichi Sugihara; Soichiro Ishihara
Journal:  Int J Colorectal Dis       Date:  2021-05-03       Impact factor: 2.571

Review 6.  Current evidence regarding the role of adjuvant chemotherapy in rectal cancer patients with pathologic complete response after neoadjuvant chemoradiotherapy: a systematic review and meta-analysis.

Authors:  Ioannis Baloyiannis; Konstantinos Perivoliotis; Styliani Vederaki; Georgios Koukoulis; Dimitrios Symeonidis; George Tzovaras
Journal:  Int J Colorectal Dis       Date:  2021-03-27       Impact factor: 2.571

Review 7.  Rectal Cancer in 2018: A Primer for the Gastroenterologist.

Authors:  Benjamin A Goldenberg; Emma B Holliday; Ramzi M Helewa; Harminder Singh
Journal:  Am J Gastroenterol       Date:  2018-12       Impact factor: 10.864

8.  Variations of the renal function parameters in rectal cancer patients with a defunctioning loop ileostomy.

Authors:  Dragos Viorel Scripcariu; Dimitrie Siriopol; Mihaela Moscalu; Viorel Scripcariu
Journal:  Int Urol Nephrol       Date:  2018-07-04       Impact factor: 2.370

9.  Myocardial Ischemia Induced by 5-Fluorouracil: A Prospective Electrocardiographic and Cardiac Biomarker Study.

Authors:  Merete Vaage-Nilsen; Dorte L Nielsen; Anne Dyhl-Polk; Morten Schou; Kirsten K Vistisen; Anne-Sophie Sillesen; Eva Serup-Hansen; Jens Faber; Tobias W Klausen; Stig E Bojesen
Journal:  Oncologist       Date:  2020-10-07

10.  Pelvic MRI after induction chemotherapy and before long-course chemoradiation therapy for rectal cancer: What are the imaging findings?

Authors:  Marc J Gollub; Ivana Blazic; David D B Bates; Naomi Campbell; Andrea Knezevic; Mithat Gonen; Patricio Lynn; Martin R Weiser; Julio Garcia-Aguilar; Andreas M Hötker; Andrea Cercek; Leonard Saltz
Journal:  Eur Radiol       Date:  2018-10-02       Impact factor: 5.315
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.